Can Immunome's Varegacestat Data Justify What Investors Are Now Willing to Overlook?

Immunome Inc (NASDAQ: IMNM) reports first-quarter 2026 earnings on May 11, 2026, with analysts expecting a loss of $0.60 per share. The biotechnology company faces a critical test as investors assess whether its clinical pipeline can justify a valuation that has climbed 25% above its 200-day moving average despite persistent losses. With 14 of 15 analysts rating the stock a Strong Buy and a consensus price target implying 58% upside, the question is whether IMNM can demonstrate progress that validates the Street's bullish conviction.

Part 1: Earnings Preview

Immunome is a clinical-stage biotechnology company developing targeted therapies for oncology and infectious diseases, leveraging its proprietary antibody discovery platform to identify novel therapeutic candidates. The company's pipeline focuses on addressing unmet medical needs in cancer treatment, with multiple programs advancing through clinical development.

For the quarter ending March 2026, analysts expect IMNM to report a loss of $0.60 per share when it announces results on May 11, 2026. The company most recently reported fourth-quarter 2025 results with an actual loss of $0.75 per share. Compared to the same quarter last year, when IMNM posted a loss of $0.52 per share, the consensus estimate represents a 15.38% deterioration year-over-year, reflecting increased R&D spending as clinical programs advance.

Three key themes define this earnings story:

Clinical Pipeline Advancement: Investors are focused on updates regarding IMNM's lead oncology programs, particularly any data readouts or enrollment milestones that could validate the company's therapeutic approach. Progress here would justify the elevated valuation and support the bullish analyst consensus.

Cash Runway and Burn Rate: With operating losses exceeding $200 million annually and a profit margin of -3,061%, the company's ability to fund operations through key clinical milestones remains paramount. Any commentary on cash position, burn rate trajectory, or potential financing needs will be scrutinized.

Regulatory Pathway Clarity: As programs mature, investors seek greater visibility into regulatory strategies, potential approval timelines, and commercial opportunities. Management's ability to articulate a clear path to market will be critical for maintaining investor confidence.

Analyst commentary ahead of the release emphasizes the company's "proprietary antibody discovery platform" and its potential to generate multiple clinical candidates. The Street's overwhelmingly bullish stance—with 14 Strong Buy ratings and a mean price target of $35.54—suggests confidence in the pipeline's long-term value, though near-term losses are expected to persist as development costs mount.

Part 2: Historical Earnings Performance

Immunome has delivered a mixed earnings track record over the past four quarters, with two beats and two misses against analyst estimates. The company beat expectations by 21.21% in Q1 2025 (reporting -$0.52 versus -$0.66 estimated) and by 3.85% in Q2 2025 (reporting -$0.50 versus -$0.52 estimated). However, the trend reversed in the second half of 2025, with IMNM missing estimates by 14.04% in Q3 (reporting -$0.65 versus -$0.57 estimated) and by 15.38% in Q4 (reporting -$0.75 versus -$0.65 estimated).

The deteriorating pattern in the latter half of 2025 is notable, with losses deepening sequentially from -$0.50 in Q2 to -$0.75 in Q4. This 50% increase in quarterly losses suggests accelerating cash burn, likely driven by advancing clinical trials and expanded R&D activities. The Q4 miss of 15.38% was particularly significant, as it represented the largest negative surprise in the four-quarter period and came despite analysts having already revised estimates higher.

For the upcoming Q1 2026 report, analysts are projecting a loss of -$0.60 per share, which would represent a modest improvement from the -$0.75 reported in Q4 2025 but still worse than the -$0.52 posted in the year-ago quarter. Given the recent pattern of misses and deepening losses, investors should be prepared for the possibility that actual results could come in below the consensus estimate, particularly if clinical spending remains elevated.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Immunome typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price behavior shows significant volatility around IMNM earnings releases, with an average absolute Day 0 move of 3.95% and Day +1 move of 3.10%. The most dramatic reaction occurred in November 2024, when the stock plunged 7.21% on Day 0 and continued lower with a 3.88% decline on Day +1, coinciding with a substantial earnings miss. Conversely, the May 2025 report saw a 6.43% Day 0 surge despite the company beating estimates.

The data reveals directional unpredictability—positive and negative moves are roughly balanced across the eight-quarter sample, with no clear pattern linking earnings surprises to price direction. The average Day 0 range of 6.29% and Day +1 range of 7.48% indicate substantial intraday volatility, suggesting active trading and position adjustments as investors digest results and management commentary. The most recent March 2026 report saw a 3.02% Day 0 decline followed by a 4.55% Day +1 rally, demonstrating how initial reactions can quickly reverse as the market processes clinical updates and forward guidance.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 1.67% for the May 15 expiration, which is substantially below the stock's historical average earnings move of 3.95% on Day 0 and 3.10% on Day +1. This suggests options traders are anticipating a more muted reaction than IMNM has typically delivered, potentially underpricing volatility risk for investors holding positions through the announcement.

Part 3: What Analysts Are Saying

Analyst sentiment on Immunome remains overwhelmingly bullish, with 14 of 15 analysts rating the stock a Strong Buy, one Hold, and zero Sell ratings. This translates to an average recommendation of 4.87 on the 5-point scale, reflecting near-unanimous conviction in the company's long-term prospects. The consensus price target of $35.54 implies 58% upside from the current price of $22.44, with individual targets ranging from $30.00 to $40.00.

The analyst consensus has remained unchanged over the past month, with the same 14 Strong Buy and 1 Hold configuration persisting. This stability suggests the Street is maintaining its bullish thesis despite the company's recent earnings misses and deepening quarterly losses. The lack of any Sell ratings is particularly notable given IMNM's negative profit margins exceeding -3,000% and ongoing cash burn exceeding $200 million annually.

The 58% implied upside to the mean price target indicates analysts believe the market is significantly undervaluing IMNM's clinical pipeline and commercial potential. Even the most conservative $30.00 target implies 34% upside, suggesting the analyst community sees limited downside risk at current levels. This bullish positioning likely reflects confidence in upcoming clinical data readouts, regulatory progress, or potential partnership opportunities that could validate the company's therapeutic approach and justify a higher valuation multiple.

Part 4: Technical Picture

The Barchart Technical Opinion rates IMNM as a Buy at 72%, unchanged from both one week ago and one month ago, indicating stable technical momentum heading into the earnings release. The stock is trading at $22.44, positioned above its 50-day ($21.99), 100-day ($22.36), and 200-day ($17.93) moving averages but below its 5-day ($22.87), 10-day ($23.02), and 20-day ($23.27) moving averages. This configuration suggests a longer-term uptrend that has encountered near-term resistance.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum is positive but not overwhelming, reflecting recent consolidation below the 20-day average
• Medium-term (50% Buy): Moderate buy signal suggests the intermediate trend remains constructive, supported by the stock's position above the 50-day moving average
• Long-term (100% Buy): Strong buy signal reflects robust longer-term momentum, with the stock trading 25% above its 200-day moving average

Trend Characteristics: The Average strength trend that is Weakening suggests IMNM's technical setup is losing some momentum heading into earnings, with recent price action failing to sustain the rally that carried the stock well above its long-term averages.

The stock's position above all major long-term moving averages provides a supportive technical foundation, but the recent failure to hold above short-term averages (5-day, 10-day, 20-day) indicates profit-taking or consolidation pressure. The 25% premium to the 200-day moving average suggests the stock has already priced in considerable optimism, leaving it vulnerable to disappointment if earnings or clinical updates fall short of expectations. The Weakening direction of the trend, combined with the stock trading below its near-term averages, creates a cautiously mixed technical setup—the long-term uptrend remains intact, but near-term momentum has stalled, making the earnings reaction potentially decisive for determining whether IMNM can resume its advance or faces further consolidation.